Sezai Vatansever

Istanbul, 34104, Turkey

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 40 publications

Real‑world efficacy and safety data of immune checkpoint inhibitors in Turkish patients with metastatic melanoma: A Turkish oncology group retrospective study.

Real‑world efficacy and safety data of immune checkpoint inhibitors in Turkish patients with metastatic melanoma: A Turkish oncology group retrospective study.

Journal: Molecular and clinical oncology

Published: December 17, 2024

Factors Affecting Recurrence and Survival in Stage IIA Colon Cancer Patients.

Factors Affecting Recurrence and Survival in Stage IIA Colon Cancer Patients.

Journal: Oncology

Published: February 18, 2024

Isolated Adrenal Metastases of Castration-Resistant Prostate Cancer: Excellent Response to 177 Lu-PSMA With No Adrenal Insufficiency.

Isolated Adrenal Metastases of Castration-Resistant Prostate Cancer: Excellent Response to 177 Lu-PSMA With No Adrenal Insufficiency.

Journal: Clinical nuclear medicine

Published: November 22, 2023

Efficacy of Lapatinib Plus Capecitabine After TDM-1 in HER2-Positive Metastatic Breast Cancer Patients.

Efficacy of Lapatinib Plus Capecitabine After TDM-1 in HER2-Positive Metastatic Breast Cancer Patients.

Journal: Indian journal of surgical oncology

Published: September 25, 2023

Prognostic Value of Inflammation and Nutrition-Based Scores in Non-Small Cell Lung Cancer.

Prognostic Value of Inflammation and Nutrition-Based Scores in Non-Small Cell Lung Cancer.

Journal: Medical principles and practice : international journal of the Kuwait University, Health Science Centre

Published: July 13, 2023

Rechallenge of Trastuzumab-based Therapy in HER2-Positive Breast Cancer Patients who Progressed Under TDM-1.

Rechallenge of Trastuzumab-based Therapy in HER2-Positive Breast Cancer Patients who Progressed Under TDM-1.

Journal: Indian journal of surgical oncology

Published: July 11, 2023

Prognostic Factors Influencing Progression-Free Survival in HER2-Positive Metastatic Breast Cancer Patients Who Were Treated With A Combination of Lapatinib and Capecitabine.

Prognostic Factors Influencing Progression-Free Survival in HER2-Positive Metastatic Breast Cancer Patients Who Were Treated With A Combination of Lapatinib and Capecitabine.

Journal: European journal of breast health

Published: December 12, 2022

Outcomes and Prognostic Factors in HER2-Positive Metastatic Breast Cancer Patients Who Had Developed Brain Metastasis in the Treatment Process.

Outcomes and Prognostic Factors in HER2-Positive Metastatic Breast Cancer Patients Who Had Developed Brain Metastasis in the Treatment Process.

Journal: Oncology

Published: October 24, 2022

Immune checkpoint inhibitors: Assessment of the performance and the agreement of iRECIST, irRC, and irRECIST.

Immune checkpoint inhibitors: Assessment of the performance and the agreement of iRECIST, irRC, and irRECIST.

Journal: Journal of cancer research and therapeutics

Published: September 08, 2022

Evaluation of clinicopathological features determining treatment response in patients with ALK mutant NSCLC.

Evaluation of clinicopathological features determining treatment response in patients with ALK mutant NSCLC.

Journal: Medicine

Published: August 31, 2022

The Significance of Preoperative Computed Tomography Features in the Prediction of Overall Survival in Gastric Cancer: A Retrospective Analysis.

The Significance of Preoperative Computed Tomography Features in the Prediction of Overall Survival in Gastric Cancer: A Retrospective Analysis.

Journal: Sisli Etfal Hastanesi tip bulteni

Published: August 10, 2022

The effectiveness and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early-stage human epidermal growth factor receptor 2-positive breast cancer: Turkish Oncology Group study.

The effectiveness and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early-stage human epidermal growth factor receptor 2-positive breast cancer: Turkish Oncology Group study.

Journal: Anti-cancer drugs

Published: June 15, 2022

Showing 1-12 of 40

Last Updated: 09/26/2026